Fig. 3From: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trialHIV RNA at M6 for each volunteer. The HIV RNA level (copies/mL) is displayed on a logarithmic scale. For each group, the median is shown as a grey line Back to article page